<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23592">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799654</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-O-H-1612</org_study_id>
    <nct_id>NCT02799654</nct_id>
  </id_info>
  <brief_title>Excia T Cementless EBRA Study</brief_title>
  <official_title>Non-Interventional Post Market Clinical Follow-up Study Excia T® Cementless EBRA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aesculap AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aesculap AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this Post Market Clinical Follow-up Study (PMCF Study), the short-term clinical and
      radiological results of the cementless Excia T® prosthesis in routine clinical use shall be
      assessed and the migration taking place in the first 24 months evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Subsidence over time of Excia T® stem (EBRA-FCA)</measure>
    <time_frame>discharge (approx. 1 week postop), 3, 12 and 24 months postoperative</time_frame>
    <description>The subsidence of the Excia T stem will be measured with Ein-Bild-Röntgen-Analysis Femoral Component Analysis (EBRA-FCA). EBRA allows a non-invasive measurement of routinely taken A/P radiographs. Necessary is a series of at least four x-rays that can be read by the EBRA software.
The whole implant must be visible on the A/P x-ray, as well as the greater and lesser trochanter.
Subsidence shall be measured on the follow-up x-rays in comparison to the discharge x-rays.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Results over time (Harris Hip Score)</measure>
    <time_frame>preoperative, discharge (approx. 1 week postop), 3, 12 and 24 months postoperative</time_frame>
    <description>The clinical assessment will be done with the Harris Hip Score (HHS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life over time (EQ-5D-5L)</measure>
    <time_frame>preoperative, discharge (approx. 1 week postop), 3, 12 and 24 months postoperative</time_frame>
    <description>The generic patient reported outcome score EQ-5D-5L will be used for the assessment of quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteolysis over time (localized bone resorption)</measure>
    <time_frame>3, 12 and 24 months postoperative</time_frame>
    <description>radiological evaluation will be done according to the (A/P) Gruen zones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiolucent lines over time</measure>
    <time_frame>3, 12 and 24 months postoperative</time_frame>
    <description>radiological evaluation will be done according to the (A/P) Gruen zones: ≤1mm, 1-2mm, ≥2mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical thinning</measure>
    <time_frame>3, 12 and 24 months postoperative</time_frame>
    <description>radiological evaluation will be done according to the (A/P) Gruen zones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertrophy</measure>
    <time_frame>3, 12 and 24 months postoperative</time_frame>
    <description>radiological evaluation will be done according to the (A/P) Gruen zones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical Alignment over time</measure>
    <time_frame>discharge (approx. 1 week postop), 3, 12 and 24 months postoperative</time_frame>
    <description>any change of the A/P implant angle (varus / valgus alignment) as assessed with EBRA-FCA will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events / Serious Adverse Events</measure>
    <time_frame>until 24 months postoperative</time_frame>
    <description>Rates of Adverse Events / Serious Adverse Events are recorded</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Arthritis, Degenerative</condition>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Hip Fractures</condition>
  <condition>Femur Head Necrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with indication for cementless primary Total Hip Arthroplasty
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written patient consent to study participation

          -  Age &gt; 18 years

          -  Indication for primary THA with cementless Excia T® stem

        Exclusion Criteria:

          -  Pregnancy

          -  THA after fracture

          -  Rheumatoid arthritis

          -  Systemic disorders, treated with Cortisone or other pharmaceuticals, potentially
             compromising the bone quality

          -  Patient physically or mentally not able to follow the postoperative examination
             routine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne-Katrin Wacker</last_name>
    <phone>+49-7461-95-1509</phone>
    <email>anne_katrin.wacker@bbraun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Weiler, Dr.</last_name>
    <phone>+49-7461-95-2721</phone>
    <email>andrea.weiler@aesculap.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prof. Dr. med. E. Mayr</name>
      <address>
        <city>Celle</city>
        <zip>29223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 10, 2016</lastchanged_date>
  <firstreceived_date>June 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total Hip Arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Femur Head Necrosis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
